$NUOX · NuvOx Therapeutics, Inc.
NuvOx Therapeutics filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 2,860,000 shares of common stock at an estimated price range of $6.00 to $8.00 per share, implying gross proceeds of approximately $17.2 million to $22.9 million. The company intends to list on NYSE American under the symbol "NUOX." NuvOx is a clinical-stage biopharmaceutical company developing NanO₂, an intravenous oxygen therapeutic targeting hypoxia-driven diseases including acute ischemic stroke, glioblastoma multiforme (GBM), acute respiratory distress syndrome (ARDS), and sickle
- Proposed IPO of 2.86M shares at $6.00–$8.00 per share, targeting $17.2M–$22.9M in gross proceeds.
- Lead candidate NanO₂ is in three active clinical trials: Phase IIb GBM (93 patients enrolled), Phase IIb stroke (23 treated), and Phase Ib/2
- NanO₂ holds FDA orphan drug designation for GBM (2015) and sickle cell anemia (2016).
- No pharmaceutical treatments are currently approved for hypoxia in acute ischemic stroke, GBM, or ARDS.
- Company has never generated revenue and has no approved products; IPO proceeds fund trials through Phase II ARDS and Phase III GBM prep.
Price data unavailable.
A pre-revenue biotech with no approved products and a single clinical candidate is tapping public markets to fund late-stage trials in indications where multiple prior therapies have failed.
NuvOx enters a crowded hypoxia-therapy space with no FDA-approved competitors for its target indications (stroke, GBM, ARDS). Multiple neuroprotective stroke agents have failed prior clinical trials, underscoring the high-risk nature of this development pathway.
Pre-revenue clinical-stage biotech with no approved products; NanO₂ safety data shows 49 SAEs in the ongoing Phase IIb GBM trial, including two possibly related to the drug. IPO proceeds are essential to fund operations — failure to complete the offering would materially impair the company's ability
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.